Nasim Mastouri
Nephrology · Lima, OHNPI 1710121132
Payments from drug & device makers
Across 299 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$813
- Mallinckrodt Hospital Products Inc.$566
- Vifor Pharma, Inc.$546
- Bayer$544
- Aurinia Pharma U.S., Inc.$506
- Amgen$461
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,73888%
- Education$79012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $813 |
| Mallinckrodt Hospital Products Inc. | 18 | $566 |
| Vifor Pharma, Inc. | 33 | $546 |
| Bayer | 28 | $544 |
| Aurinia Pharma U.S., Inc. | 14 | $506 |
| Amgen | 20 | $461 |
| Otsuka America Pharmaceutical, Inc. | 23 | $420 |
| Novartis | 19 | $395 |
| Calliditas Therapeutics US Inc. | 15 | $390 |
| OPKO Pharmaceuticals, LLC | 15 | $251 |
| Boehringer Ingelheim | 9 | $228 |
| Novo Nordisk | 12 | $206 |
| Akebia Therapeutics Inc | 6 | $161 |
| Ardelyx, Inc. | 3 | $157 |
| Baxter Healthcare | 4 | $152 |
| Renalytix AI, Inc. | 5 | $103 |
| Lilly USA, LLC | 4 | $77 |
| Mallinckrodt Enterprises LLC | 4 | $75 |
| Daiichi Sankyo Inc. | 4 | $68 |
| Madrigal Pharmaceuticals | 2 | $56 |
| Pfizer | 3 | $48 |
| Fresenius USA Marketing, Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $27 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| AbbVie | 1 | $23 |
| Nxstage Medical, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Urovant Sciences Inc | 1 | $16 |
| Travere Therapeutics, Inc. | 8 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPHOZAH 30 MG$102
How this compares
$6,529 in reported general payments places this provider in the 80th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 30 | $60,179 |
| KerendiaFinerenone | 42 | $39,307 |
| FarxigaDapagliflozin Propanediol | 39 | $36,914 |
| XphozahTenapanor Hcl | 11 | $28,967 |
| OzempicSemaglutide | 21 | $19,875 |
| TradjentaLinagliptin | 13 | $17,018 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $16,259 |
| RayaldeeCalcifediol | 13 | $15,698 |
| LokelmaSodium Zirconium Cyclosilicate | 36 | $15,259 |
| Cinacalcet Hcl | 17 | $8,321 |
| Potassium Citrate ErPotassium Citrate | 51 | $6,093 |
| MyrbetriqMirabegron | 11 | $4,917 |
| Bumetanide | 94 | $4,578 |
| ProsolParenteral Amino Acid 20% No.1 | 13 | $3,051 |
| Sevelamer Carbonate | 52 | $3,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $42 | $60,17930 claims |
| AstraZenecaFarxiga, Lokelma | $813 | $52,17375 claims |
| BayerKerendia | $544 | $39,30742 claims |
| Novo NordiskOzempic | $206 | $19,87521 claims |
| Boehringer IngelheimTradjenta | $228 | $17,01813 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $251 | $15,69813 claims |
| AbbVieSynthroid | $23 | $1,24319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 nephrology providers in Ohio.
Other nephrology in Lima
- Isabelle AyoubColumbus$1.6M
- Andrew LazarBeachwood$806K
- Samir ParikhColumbus$699K
- Brad RovinColumbus$625K
- Lance DworkinToledo$601K
- Mohamed SekkarieToledo$524K
- Kevin SchroederColumbus$518K
- Prabir Roy ChaudhuryCincinnati$483K
- Amit GovilCincinnati$444K
- Sankar NavaneethanCleveland$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.